NSABP B-31长期随访:曲妥珠单抗辅助治疗未致心功能或生活质量长期恶化
NSABP B-31试验对淋巴结阳性、HER2阳性早期乳腺癌患者进行长期随访,比较AC序贯紫杉醇联合或不联合曲妥珠单抗辅助治疗。中位随访8.8年,曲妥珠单抗组LVEF较基线下降>10%且<50%的发生率为3.4%(10/297),对照组为4.5%(5/110)。加用曲妥珠单抗未导致心功能、心脏症状或健康相关生活质量的长期恶化,DASI评分与年龄及合并用药相关,与是否接受曲妥珠单抗无关。
要点
- 中位随访8.8年,曲妥珠单抗组LVEF显著下降(>10%且<50%)发生率3.4%,对照组4.5%。
- 加用曲妥珠单抗未导致长期心功能、心脏症状或健康相关生活质量恶化。
- DASI问卷或可简单监测反映心功能的患者报告变化。
核心结论
- 在基线无基础心脏病的患者中,辅助蒽环类和紫杉类化疗加用曲妥珠单抗不导致心功能、心脏症状或健康相关生活质量的长期恶化。
研究设计与样本
- NSABP B-31随机试验长期随访,纳入淋巴结阳性、HER2阳性早期乳腺癌患者,辅助化疗加或不加曲妥珠单抗,对无病生存者进行LVEF(MUGA)及患者报告结局评估。
主要发现
- 中位随访8.8年,曲妥珠单抗组LVEF较基线下降>10%且<50%的发生率为3.4%(10/297),对照组为4.5%(5/110)。
- DASI评分较低与年龄及使用高血压、心脏疾病、糖尿病和高脂血症药物相关,与是否接受曲妥珠单抗无关。
关键数值与推荐
- LVEF显著下降定义为较基线下降>10%且绝对值<50%。
- 患者报告结局采用DASI、Medical Outcomes Study问卷及当前用药和合并症回顾。
临床怎么用
- 对于基线无基础心脏病的HER2阳性早期乳腺癌患者,辅助蒽环和紫杉类化疗加用曲妥珠单抗的长期心脏安全性可接受。
- DASI问卷可能作为简单有用的工具,监测反映心功能的患者报告变化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index (DASI), the Medical Outcomes Study questionnaire, and a review of current medications and comorbid conditions. Results At a median follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control group and 10 (3.4%) of 297 in the trastuzumab group had a > 10% decline in left ventricular ejection fraction from baseline to a value < 50%. Lower DASI scores correlated with age and use of medications for hypertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had received trastuzumab. Conclusion In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.
引用
- Ganz PA, Romond EH, Cecchini RS, et al. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. J Clin Oncol. 2017. PMID: 29072977. doi:10.1200/JCO.2017.74.1165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。